Tramadol, buy tramadol, antibiotics, Weight Loss drugs, weight loss herbs, weight loss herbal formula, weight loss, hair loss, hair growth, baldness, Rx Online, pharmaceuticals, DHEA, Lutein, Prescription, Prescription drug, prescription medications, alopecia.

References: Hair growth and hair loss

Oncology. 1997 Mar-Apr;54(2):108-11.
Palliative chemotherapy in non-Hodgkin's lymphoma.

Salminen E, Nikkanen V, Lindholm L.

Department of Oncology and Radiotherapy, Turku University Hospital, Finland.

GOALS OF WORK: There is a need for an effective and nontoxic chemotherapy for palliative indication in non-Hodgkin's lymphoma (NHL) patients who relapse after conventional or high-dose chemotherapy. The aim of this study was to investigate the feasibility and efficacy of peroral chemotherapy in the palliative treatment of NHL patients. PATIENTS AND METHODS: Seventeen NHL patients were treated with peroral trofosfamide (Ixoten) with an initial dose of 50 mg three times daily. The median age of the patients was 62 years (range: 45-78). Most of the patients had received multiple courses of combination chemotherapy. MAIN RESULTS: The overall response rate (complete remission and partial remission) was 53% (95% confidence interval 29-77), and median response duration was 7 months. Cross-resistance was not observed between trofosfamide and chlorambucil. Grade 1-3 hematological toxicity occurred in 16 patients. Other side effects, including mild or moderate nausea, neurotoxicity, alopecia and fatigue, did not require dose adjustments. No fatal complications occurred. CONCLUSION: Trofosfamide as a palliative regimen is feasible and effective in NHL patients even following previous heavy treatment.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9075780&dopt=Abstract

Dermatol Surg. 1996 Dec;22(12):1009-13.
Anchor scalp reduction.

Seery GE.

Hair Transplantation Clinic of Sacramento, California 95825, USA.

BACKGROUND: Unsightly scars, stretch-back, and stretch atrophy are common complications of scalp reduction. OBJECTIVE: To remove as much bald scalp as possible while preserving normal tissue integrity (e.g., thickness, vascularity) and cosmesis. METHODS: Surgical innovations anchor scalp reduction I & II, use pericranial flaps as aids to facilitate maximal reduction while limiting postoperative distraction vector forces responsible for stretch-back, stretch-atrophy, and wide scars. RESULTS: Anchor scalp reduction I consistently results in fine barely perceptible scars. Anchor scalp reduction II enables maximal bald area reduction while minimizing the incidence of stretch-back and wide scars. CONCLUSIONS: Anchor scalp reduction I is a simple innovation recommended for suturing scalp incisions where the primary objective is a fine barely discernible scar, e.g., in plastic surgery or neurosurgery. Anchor scalp reduction II is preferred for hair restoration procedures where the primary objective is maximizing reduction while minimizing stretch-back and stretch atrophy.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9078312&dopt=Abstract

Aust N Z J Med. 1997 Feb;27(1):40-4.
Activity and toxicity of docetaxel (Taxotere) in women with previously treated metastatic breast cancer.

Shapiro JD, Millward MJ, Rischin D, Davison JD, Michael M, Francis PA, Ganju V, Toner GC.

Division of Haematology and Medical Oncology, Peter MacCallum Cancer Institute, Melbourne, Vic.

BACKGROUND: Metastatic breast cancer is a major cause of cancer death in Australian women. Docetaxel is a new cytotoxic drug that has shown promise in the treatment of metastatic breast cancer in patients who have previously received other chemotherapy, particularly an anthracycline, and has recently been approved for marketing in Australia. AIM: To report the first Australian experience with docetaxel in a group of women with metastatic breast cancer. METHODS: Patients with progressive metastatic breast cancer who had previously received other chemotherapy were treated with docetaxel 75 mg/m2 or 100 mg/m2 given as a one hour infusion every three weeks. All patients received oral dexamethasone for five days starting 24 hours prior to docetaxel as prophylaxis against fluid retention. The patients' response to docetaxel and toxicity were assessed by standard criteria. RESULTS: Twenty-six patients were treated. The major toxicity was neutropenia with 92% of patients experiencing at least one episode of grade 4 (absolute neutrophil count < 0.5 x 10(9)/L) neutropenia. Hospital admission for febrile neutropenia occurred in 44% of patients with one death from sepsis. Cumulative fluid retention was observed but in only one patient was it dose-limiting. Apart from alopecia, other toxicities were infrequent and rarely serious. In 23 patients assessable for response, there were 11 partial responses (48%). Three other patients whose disease could not be assessed for response had clinical improvement. The median survival of all patients treated was eight months. CONCLUSIONS: The response rate observed with docetaxel is comparable to that seen in trials in the United States and Europe and confirms the high activity of this new cytotoxic agent. Neutropenia is the major toxicity, and consideration should be given to the use of prophylactic oral antibiotics or colony stimulating factors to try and prevent febrile episodes. Clinicians will need to balance the benefits, toxicities, and cost of docetaxel in determining the appropriateness of its use in their patients.

online pharmacy ref. source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9079252&dopt=Abstract

Natural Herbal Supplements || Hair Million herbal formula for hair loss and hair growth || Hair growth research references || Online Pharmacy : discount prescription medication ||